Aurora Cannabis Inc is seeing a significant drop in its stock price, which is raising concerns among investors.
Today, shares of Aurora Cannabis Inc (ACB.TO) are down 3.37%. This decline comes as the cannabis sector faces challenges, with the company reporting a major decrease in Canadian medical cannabis revenue and shifting its focus away from consumer markets.
Advertisement
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeAdvertisement
Market cap
$257.06M
52W high
$9.33
52W low
$3.59
1W change
+6.96%
Beta
1.34
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 34.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.56
+34.0% Upside
Current Price
C$4.15
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
36.1%
Annualized
90-Day Vol
47.5%
Annualized
Trend (90d)
-42.3%
Annualized drift
90d Mean
C$3.57
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.95 | C$3.48 – C$4.47 |
| 60 trading days | C$3.75 | C$3.15 – C$4.47 |
| 90 trading days | C$3.57 | C$2.88 – C$4.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Aurora's reliance on international markets increases while domestic sales continue to struggle.
Aurora Cannabis Inc's stock down 3.37% today
The company has reported a 25% decline in Canadian medical cannabis revenue, which is affecting its overall performance.
Bull case
Aurora's international medical cannabis sales, especially in Germany, are showing potential. This growth could help stabilize revenue in the long run.
Bear case
The sharp drop in Canadian medical cannabis revenue and the ongoing decline in consumer cannabis sales raise concerns about the company's future profitability.
Current Stock Performance
Advertisement
Aurora Cannabis Inc's stock has fallen 3.37% today, closing at CA$4.01. This decline reflects the company's ongoing struggles, particularly as it reports weaker revenue from its core Canadian medical cannabis market.
Challenges in Revenue Generation
The latest quarterly report revealed a 25% drop in Canadian medical cannabis revenue, which has fallen to CA$20.7 million. This decline is linked to changes in the federal reimbursement program that have significantly affected sales. Despite efforts to expand into international markets, the nearly 74% drop in consumer cannabis revenue continues to heavily impact Aurora's financial outlook.
Future Prospects
While Aurora is focusing on growth in international medical cannabis, particularly in Germany, the significant losses in its domestic market raise concerns. Investors should closely monitor how the company navigates these challenges and whether its strategic shift will produce the desired results in the upcoming quarters.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
